HIV patients get new hope against hepatitis b with tailored vaccine strategy
NCT ID NCT00480792
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested three different ways of giving the hepatitis B vaccine to 437 people with HIV whose CD4 counts were above 200. The goal was to see which schedule—standard dose, double dose, or skin injections—works best to protect them from hepatitis B, a virus that can cause serious liver damage in HIV patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GenHevac B Pasteur (hepatitis B vaccine)
What this could lead to
If successful, this could identify a more effective hepatitis B vaccination schedule for people with HIV, reducing their risk of severe liver disease.
What could go wrong
This trial is completed, so results are available. However, the vaccine may still be less effective in some HIV patients, and protection may not last long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital Cochin CIC de vaccinologie
Paris, 75014, France